Cleveland Biolabs Inc. (CBLI) and Incuron Announce Russian Regulatory Allowance of IND for Phase 1B Trial of CBLC137  
4/30/2012 10:03:46 AM

BUFFALO, N.Y., April 30, 2012 (GLOBE NEWSWIRE) -- Cleveland BioLabs, Inc. (Nasdaq:CBLI) and its majority-owned subsidiary, Incuron, LLC today announced that a new Investigational New Drug (IND) application for clinical testing of CBLC137 was opened with the regulatory authority of the Russian Federation.